NASDAQ:AXDX - Accelerate Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$16.76 +0.46 (+2.82 %)
(As of 01/21/2019 12:04 PM ET)
Previous Close$16.30
Today's Range$16.32 - $17.08
52-Week Range$10.23 - $30.35
Volume348,642 shs
Average Volume362,887 shs
Market Capitalization$908.37 million
P/E Ratio-14.45
Dividend YieldN/A
Beta2.51
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXDX
CUSIPN/A
Phone520-365-3100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.18 million
Book Value$2.14 per share

Profitability

Net Income$-64,020,000.00
Net Margins-1,365.75%

Miscellaneous

EmployeesN/A
Market Cap$908.37 million
OptionableOptionable

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics Inc (NASDAQ:AXDX) posted its earnings results on Tuesday, November, 6th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.41). The medical research company had revenue of $1.36 million for the quarter, compared to analyst estimates of $2.89 million. Accelerate Diagnostics had a negative net margin of 1,365.75% and a negative return on equity of 81.76%. View Accelerate Diagnostics' Earnings History.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for Accelerate Diagnostics.

What guidance has Accelerate Diagnostics issued on next quarter's earnings?

Accelerate Diagnostics updated its FY 2018 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $5.7-5.7 million, compared to the consensus revenue estimate of $6.63 million.Accelerate Diagnostics also updated its Q4 2018 guidance to EPS.

What price target have analysts set for AXDX?

4 Wall Street analysts have issued 12 month target prices for Accelerate Diagnostics' shares. Their forecasts range from $16.00 to $25.00. On average, they expect Accelerate Diagnostics' share price to reach $19.3333 in the next year. This suggests a possible upside of 15.4% from the stock's current price. View Analyst Price Targets for Accelerate Diagnostics.

What is the consensus analysts' recommendation for Accelerate Diagnostics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accelerate Diagnostics.

Has Accelerate Diagnostics been receiving favorable news coverage?

News stories about AXDX stock have trended positive recently, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.

Who are some of Accelerate Diagnostics' key competitors?

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the folowing people:
  • Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)
  • Mr. Steve Reichling, Chief Financial Officer (Age 41)
  • Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)
  • Mr. Kurt Reinhardt, Head of Operations
  • Dr. Romney M. Humphries, Chief Scientific Officer

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $16.76.

How big of a company is Accelerate Diagnostics?

Accelerate Diagnostics has a market capitalization of $908.37 million and generates $4.18 million in revenue each year. The medical research company earns $-64,020,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is http://www.acceleratediagnostics.com.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]


MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  380
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe AXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel